Marisa Wexler, MS,  senior science writer—

As part of the company’s Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, Bayer is giving a total of $1 million to seven research projects related to pulmonary hypertension. The awards are aimed at projects focused on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), which makes the…

Apabetalone (RVX-208), Resverlogix‘s experimental treatment for pulmonary arterial hypertension (PAH), was well-tolerated in a small clinical trial, the company announced. The trial met its primary goal of adding apabetalone to standard care to improve pulmonary vascular resistance (PVR), a measure that reflects the internal resistance to blood…

For premature babies who are at high risk of pulmonary hypertension (PH) and other cardiovascular complications, consuming human breast milk in the first year of life is associated with better heart function, a new study found. “Preterm infants have abnormal heart function,” Afif EL-Khuffash, MD, the study’s lead author, said…

Early treatment with Janssen’s Uptravi (selexipag) can halve the risk of disease progression for people with pulmonary arterial hypertension (PAH), a new analysis found. The results showed patients treated with Uptravi within six months of PAH diagnosis saw their risk of disease progression reduced by 52% compared with…

Cereno Scientific is planning to begin a Phase 2 clinical trial of CS1 — the company’s lead therapy candidate for pulmonary arterial hypertension (PAH) — this September, following clearance from the U.S. Food and Drug Administration (FDA). The upcoming trial will use Abbott‘s CardioMEMS HF System, a…

Levosimendan, an investigational treatment for pulmonary hypertension and heart failure with preserved ejection fraction, or PH-HFpEF — which showed positive results in a recent clinical trial — may work by reducing the amount of blood putting pressure on the walls of blood vessels, a new analysis suggests. The…

In late July, the U.S. Food and Drug Administration (FDA) approved a new formulation of Janssen‘s Uptravi (selexipag) for use by people with pulmonary arterial hypertension (PAH). Uptravi already was available as an oral tablet. The new formulation is intravenous (IV) — meaning it is administered by an…

The U.S. Food and Drug Administration (FDA) has approved an intravenous form of Uptravi (selexipag) — one infused directly into the bloodstream — for people with pulmonary arterial hypertension (PAH) temporarily unable to take oral medicines. The new intravenous, or IV, formulation is intended to prevent treatment interruptions in adults…

A protein called TIFA is elevated in the blood cells of people with pulmonary arterial hypertension (PAH), suggesting this protein is involved in the biological processes that drive the disease, according to a new study. The findings were published in the journal Scientific Reports, in the study, “…

An upcoming series of educational virtual events for people with pulmonary arterial hypertension (PAH) and their caregivers will offer insights and perspectives about how to manage life with PAH. The National Broadcast Series will include three talks from August to October. Each of the one-hour talks is scheduled to…

Dosing has begun in a clinical trial testing AER-901, Aerami Therapeutics‘ inhaled formulation of imatinib, which is being investigated as a potential treatment for pulmonary arterial hypertension (PAH). “We are pleased to announce that the dosing of subjects in our Phase 1 trial is ongoing and that we expect to…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PT001, an investigational treatment for pulmonary arterial hypertension (PAH). The FDA gives this designation to therapies with the potential to treat rare disorders, defined as those that affect fewer than 200,000 people in the U.S. The designation…